Gemcitabine
Gemcitabine, Gemzar, Infugem, Dacogen (gemcitabine) is a small molecule pharmaceutical. Gemcitabine was first approved as Gemcitabine on 1996-05-15. It is used to treat breast neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic ductal carcinoma in the USA. It has been approved in Europe to treat myeloid leukemia. The pharmaceutical is active against ribonucleoside-diphosphate reductase subunit M2 and ribonucleoside-diphosphate reductase large subunit. Gemzar's patent is valid until 2033-07-01 (FDA).
| Trade Name | Dacogen |
|---|---|
| Common Name | Gemcitabine |
| Indication | breast neoplasms, myeloid leukemia, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic ductal carcinoma |
| Drug Class | Nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
